Your browser doesn't support javascript.
loading
Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT).
Bolm, Louisa; Zemskov, Sergii; Zeller, Maria; Baba, Taisuke; Roldan, Jorge; Harrison, Jon M; Petruch, Natalie; Sato, Hiroki; Petrova, Ekaterina; Lapshyn, Hryhoriy; Braun, Ruediger; Honselmann, Kim C; Hummel, Richard; Dronov, Oleksii; Kirichenko, Alexander V; Klinkhammer-Schalke, Monika; Kleihues-van Tol, Kees; Zeissig, Sylke R; Rades, Dirk; Keck, Tobias; Fernandez-Del Castillo, Carlos; Wellner, Ulrich F; Wegner, Rodney E.
Afiliação
  • Bolm L; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Zemskov S; Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, 23562 Luebeck, Germany.
  • Zeller M; Department of General Surgery, Bogomolets National Medical Unoversity, 01601 Kyiv, Ukraine.
  • Baba T; Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, 23562 Luebeck, Germany.
  • Roldan J; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Harrison JM; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Petruch N; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Sato H; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Petrova E; Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, 23562 Luebeck, Germany.
  • Lapshyn H; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Braun R; Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, 23562 Luebeck, Germany.
  • Honselmann KC; Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, 23562 Luebeck, Germany.
  • Hummel R; Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, 23562 Luebeck, Germany.
  • Dronov O; Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, 23562 Luebeck, Germany.
  • Kirichenko AV; Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, 23562 Luebeck, Germany.
  • Klinkhammer-Schalke M; Department of General Surgery, Bogomolets National Medical Unoversity, 01601 Kyiv, Ukraine.
  • Kleihues-van Tol K; Division of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA 15224, USA.
  • Zeissig SR; German Cancer Registry Group, Society of German Tumor Centers-Network for Care, Quality and Research in Oncology, 14057 Berlin, Germany.
  • Rades D; German Cancer Registry Group, Society of German Tumor Centers-Network for Care, Quality and Research in Oncology, 14057 Berlin, Germany.
  • Keck T; Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, 97070 Wuerzburg, Germany.
  • Fernandez-Del Castillo C; Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Campus Luebeck, 23538 Luebeck, Germany.
  • Wellner UF; Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, 23562 Luebeck, Germany.
  • Wegner RE; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Cancers (Basel) ; 14(4)2022 Feb 09.
Article em En | MEDLINE | ID: mdl-35205616
ABSTRACT
(1)

Background:

The aim of this study is to assess perioperative therapy in stage IA-III pancreatic cancer cross-validating the German Cancer Registry Group of the Society of German Tumor Centers-Network for Care, Quality, and Research in Oncology, Berlin (GCRG/ADT) and the National Cancer Database (NCDB). (2)

Methods:

Patients with clinical stage IA-III PDAC undergoing surgery alone (OP), neoadjuvant therapy (TX) + surgery (neo + OP), surgery+adjuvantTX (OP + adj) and neoadjuvantTX + surgery + adjuvantTX (neo + OP + adj) were identified. Baseline characteristics, histopathological parameters, and overall survival (OS) were evaluated. (3)

Results:

1392 patients from the GCRG/ADT and 29,081 patients from the NCDB were included. Patient selection and strategies of perioperative therapy remained consistent across the registries for stage IA-III pancreatic cancer. Combined neo + OP + adj was associated with prolonged OS as compared to neo + OP alone (17.8 m vs. 21.3 m, p = 0.012) across all stages in the GCRG/ADT registry. Similarly, OS with neo + OP + adj was improved as compared to neo + OP in the NCDB registry (26.4 m vs. 35.4 m, p < 0.001). (4)

Conclusion:

The cross-validation study demonstrated similar concepts and patient selection criteria of perioperative therapy across clinical stages of PDAC. Neoadjuvant therapy combined with adjuvant therapy is associated with improved overall survival as compared to either therapy alone.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article